Amedisys Inc (AMED) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Amedisys Inc (NASDAQ:AMED) have been assigned an average rating of “Buy” from the sixteen research firms that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $105.50.

Several analysts recently weighed in on the company. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Thursday. Benchmark upgraded Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price target on the stock in a report on Tuesday, October 30th. Craig Hallum lowered Amedisys from a “buy” rating to a “hold” rating and decreased their price target for the company from $116.00 to $104.00 in a report on Friday, October 26th. Robert W. Baird increased their price target on Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday, October 11th. Finally, SunTrust Banks increased their price target on Amedisys to $130.00 and gave the company a “buy” rating in a report on Thursday, October 11th.

Shares of AMED traded up $1.46 during mid-day trading on Monday, hitting $120.50. 476,741 shares of the stock were exchanged, compared to its average volume of 654,049. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of 54.52, a price-to-earnings-growth ratio of 1.76 and a beta of 1.22. Amedisys has a 52-week low of $49.80 and a 52-week high of $127.38. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.18. The business had revenue of $417.34 million for the quarter, compared to analysts’ expectations of $411.05 million. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.56 EPS. On average, sell-side analysts expect that Amedisys will post 3.58 earnings per share for the current year.

In other Amedisys news, insider David L. Kemmerly sold 3,375 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $117.44, for a total value of $396,360.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now directly owns 11,818 shares in the company, valued at $1,438,368.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,273 shares of company stock valued at $1,217,456. 2.60% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Amedisys by 7.5% in the second quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock worth $459,945,000 after acquiring an additional 377,153 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Amedisys by 14.6% in the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock worth $116,731,000 after acquiring an additional 118,936 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Amedisys by 218.9% in the third quarter. Acadian Asset Management LLC now owns 609,586 shares of the health services provider’s stock worth $76,177,000 after acquiring an additional 418,424 shares during the last quarter. Rothschild Asset Management Inc. boosted its stake in shares of Amedisys by 0.3% in the second quarter. Rothschild Asset Management Inc. now owns 447,262 shares of the health services provider’s stock worth $38,223,000 after acquiring an additional 1,278 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Amedisys by 141.4% in the third quarter. Alliancebernstein L.P. now owns 396,533 shares of the health services provider’s stock worth $49,551,000 after acquiring an additional 232,255 shares during the last quarter. 93.58% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Further Reading: What are the Benefits of Index Funds?

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply